• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell

    10/31/23 6:50:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email

    PARSIPPANY, N.J., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company, announced it will ring the Nasdaq opening bell today, in recognition of National Diabetes Awareness Month in November. The coming year is also a time to celebrate the company's heritage in providing solutions to people living with diabetes, including 100 years since the development and launch of the first syringe dedicated to insulin delivery.

    Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diabetes Education and Camping Association (DECA), the Diabetes Foundation, Taking Control of Your Diabetes (TCOYD), The Diabetes Link, and The diaTribe Foundation are joining embecta at the Nasdaq MarketSite to ring the opening bell.

    "It's an honor to ring the Nasdaq Opening Bell today as we commemorate the beginning of Diabetes Awareness Month with our partners who are dedicated to the well-being of those living with diabetes," said Devdatt "Dev" Kurdikar, Chief Executive Officer of embecta. "embecta is grateful to work alongside people with diabetes, caregivers, healthcare providers, and advocacy organizations that are committed to improving access to education, creating community and helping people live a life unlimited by diabetes."

    Today, 1 in 10 adults around the world, an estimated 537 million people, live with diabetes1 and almost half don't know they have it. embecta is committed to addressing this challenge through innovative solutions and partnerships and leveraging its wealth of talent and 100-year legacy in insulin delivery to empower people with diabetes to live their best life.

    "The close-knit diabetes community grows even stronger and more united as we work together to deepen our understanding about diabetes and evolve the pathway to finding a cure," said Deborah Dugan, Chief Executive Officer of Beyond Type 1 and Beyond Type 2. "We are all committed to changing what it means to live with diabetes, and we are profoundly grateful to partner with embecta to support and embrace this mission."

    "Providing people with the educational, management, support and clinical resources they need to live a healthier life with diabetes takes a collaborative effort across the entire healthcare continuum," said Matthew Hornberger, Chief Executive Officer, ADCES. "We're pleased to join embecta and these mission-driven advocacy organizations to bring more awareness to the unique needs of people living with diabetes."

    The bell ringing ceremony will be streamed live via Nasdaq's Facebook page. Additionally, highlights from the ceremony will be shared across embecta's social media channels. Please visit embecta.com for additional information regarding Diabetes Awareness Month.

    About embecta 

    embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter. 

    About Association of Diabetes Care & Education Specialists

    Association of Diabetes Care & Education Specialists (ADCES) is an interprofessional membership organization dedicated to improving prediabetes, diabetes and cardiometabolic care through innovative education, management and support. With more than 12,000 professional members including nurses, dietitians, pharmacists, and others, ADCES has a vast network of practitioners working to optimize care and reduce complications. ADCES offers an integrated care model that lowers the cost of care, improves experiences and helps its members lead so better outcomes follow. For more information, visit adces.org.

    About Beyond Type 1 and Beyond Type 2

    Beyond Type 1 is a global nonprofit dedicated to the diabetes community. The organization serves the largest digital audience of any diabetes nonprofit with the mission to help people living with diabetes stay alive and thrive. Through peer support programs, global campaigns and digital platforms, Beyond Type 1 is uniting the global diabetes community—across all types of diabetes—helping to change what it means to live with chronic illness. For more information, visit beyondtype1.org or beyondtype2.org.

    About Camp Nejeda

    Camp Nejeda has been providing summer camp programs for kids with T1D since 1958. The camp continues to be operated by the Camp Nejeda Foundation, Inc., an independent nonprofit organization whose mission is to enhance the lives of people with type 1 diabetes and their families through education, empowerment, camaraderie, supportive programs, and fun. For more information about Camp Nejeda's newest programs, visit campnejeda.org.

    About Children with Diabetes

    Children with Diabetes is an Ohio-based 501(c)(3) non-profit organization dedicated to providing education and support to families living with type 1 diabetes. Children with Diabetes focuses on care today, to prepare for a cure tomorrow. As a global resource, they provide support, education and inspiration to empower families and all people living with diabetes to enjoy healthy, enriched lives. For more information, visit childrenwithdiabetes.com.

    About the Diabetes Education and Camping Association

    The Diabetes Education and Camping Association (DECA) is a non-profit organization that unites the global diabetes camping community. DECA provides resources and leadership to over 400 diabetes camps worldwide. They also assist parents and families in making the connection to a diabetes camp. DECA's mission is to advance programs that impact the lives of children living with diabetes. They hope to help campers gain the knowledge and confidence they need to live successful lives with diabetes. For more information, visit diabetescamps.org.

    About the Diabetes Foundation

    The Diabetes Foundation (DF) is a comprehensive and reliable source of help, hope and better health for children, adults and their families living in New Jersey. The Diabetes Foundation offers free education and support programs in partnership with medical, health and wellness professionals to ensure that individuals with prediabetes, Type 1, Type 2, or gestational diabetes have the knowledge and tools necessary to reduce their risk of developing diabetes or to delay or avoid the long-term complications of living with uncontrolled blood sugar. For more information, visit diabetesfoundationinc.org.

    About Taking Control of Your Diabetes

    Guided by the belief that every person with diabetes has the right to live a healthy, happy and productive life, Taking Control Of Your Diabetes® (TCOYD) educates and motivates people with diabetes to take a more active role in their condition and provides innovative and integrative continuing diabetes education to medical professionals caring for people with diabetes. Taking Control Of Your Diabetes is a 501(c)(3) Nonprofit Charitable Educational Organization. For more information, visit tcoyd.org.

    About The Diabetes Link

    The Diabetes Link is the only national organization that specializes in ensuring all young adults (ages 17-30) living with diabetes can thrive. The Link provides accessible opportunities, resources, community and peer support which empower young adults with diabetes to live a life without limits. The Links' mission is delivered through in-person (college chapter network) and online peer support communities (a private discord server), a free online educational hub that features resources developed for young adults, by young adults, in partnership with clinical experts. Signature programs include the Off to College, which prepares both future college students and their parents for the transition, the NextGen Fellowship for future diabetes industry leaders. For more information, visit thediabeteslink.org.

    About The diaTribe Foundation

    The diaTribe Foundation was founded with a mission to improve the lives of people with diabetes and prediabetes and to advocate for action. They are committed to helping people with diabetes live happier, healthier, and more hopeful lives through their diaTribe Learn publication. They also aim to influence the national conversation by bringing the patient point of view to the FDA and to other policy makers, improving diabetes literacy in the media, and convening the world's brightest minds to develop innovative solutions through strategic and global initiatves such as the Time in Range Coalition (www.timeinrange.org) and our efforts in highlighting how stigma affects people with diabetes (www.dstigmatize.org). For more information, visit diatribe.org.

    Contacts: 
      
    Media Investors 
    Christian GlazarPravesh Khandelwal
    Sr. Director, Corporate Communications VP, Head of Investor Relations
    908-821-6922551-264-6547 
    Contact Media RelationsContact IR

    1 International Diabetes Federation



    Primary Logo

    Get the next $EMBC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Financials

    Live finance-specific insights

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta to Report Fiscal Second Quarter 2025 Financial Results

      PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 9, 2025, via the embecta investor re

      4/21/25 5:00:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/8/24 10:57:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/7/24 4:21:15 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Embecta Corp.

      SC 13G - Embecta Corp. (0001872789) (Subject)

      10/25/24 5:45:30 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    SEC Filings

    See more

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Embecta Corp.

      10-Q - Embecta Corp. (0001872789) (Filer)

      5/9/25 11:45:56 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      5/9/25 6:56:44 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Embecta Corp. (0001872789) (Filer)

      2/14/25 4:30:30 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Embecta Corp. with a new price target

      Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

      4/10/25 12:41:09 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

      12/2/24 6:56:10 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. upgraded by BTIG Research with a new price target

      BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

      11/27/24 7:22:14 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta to host Analyst and Investor Day on May 22, 2025

      PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City. Dev Kurdikar, President & Chief Executive Officer, and Jake Elguicze, Chief Financial Officer, will be joined by members of the embecta leadership team to present strategic and business overview, including value creation opportunities, the company's financial profile and its long-term objectives. To register for the webcast, please go to: embecta Analyst & Investor Day Webcast Registration. Visit InvestorDay.embecta.com

      4/28/25 7:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

      WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

      6/20/24 7:30:00 AM ET
      $EMBC
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EMBC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:25:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:22:22 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z covered exercise/tax liability with 5,285 shares, decreasing direct ownership by 4% to 139,439 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:20:11 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/25/25 4:26:16 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/12/24 7:08:59 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care